Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Hypoglycemic effect of DL-aminocarnitine in streptozotocin diabetic mice: inhibition of gluconeogenesis

Conference · · Fed. Proc., Fed. Am. Soc. Exp. Biol.; (United States)
OSTI ID:5013755
DL-Aminocarnitine and palmitoyl-DL-aminocarnitine are potent, non-covalent inhibitors of carnitine palmitoyl transferase. In both diabetic and non-diabetic fasted mice, DL-aminocarnitine (0.3 mmol/kg) and palmitoyl-DL-aminocarnitine (0.1 mmol/kg) decrease the blood concentration of ketone bodies to levels observed in fed control mice. Both carnitine palmitoyltransferase inhibitors also normalize plasma glucose levels in diabetic mice. The hypoglycemic effect is maximal at 8 hours, the continues for at least 12 hours. In the present studies the authors have used (/sup 14/C)alanine, a pyruvate precursor, to prove the effect of aminocarnitine on gluconeogenesis. Diabetic mice given L-(U-/sup 14/C)alanine (1 mmol/kg) by intraperitoneal injection convert 10-15% of the administered dose to (/sup 14/C)glucose after 10 min; less than 0.1% of the radioactivity is recovered in glycogen. If 0.3 mmol/kg aminocarnitine is given subcutaneously 1 hr prior to giving (/sup 14/C)analine, the radioactivity recovered in plasma glucose is reduced by approximately 40%. The authors conclude that the hypoglycemic effect of DL-aminocarnitine in diabetic mice is due, at least in part, to inhibition of gluconeogenesis. The possibility that aminocarnitine also stimulates glucose utilization in diabetic animals is not excluded.
Research Organization:
Cornell Univ. Medical College, New York, NY
OSTI ID:
5013755
Report Number(s):
CONF-8606151-
Conference Information:
Journal Name: Fed. Proc., Fed. Am. Soc. Exp. Biol.; (United States) Journal Volume: 45:6
Country of Publication:
United States
Language:
English